Psyence Biomedical (PBM) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Radiopharm Theranostics (RADX) has outperformed Psyence Biomedical (PBM) over the past year, losing 84.8% versus a loss of 96.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBM | RADX |
|---|---|---|
| Share price | $4.97 | $1.13 |
| Market cap | — | $16.49M |
| 1-day change | -2.93% | +1.80% |
| YTD return | -83.10% | -78.35% |
| 1-year return | -96.56% | -84.83% |
| EPS (TTM) | $-12.56 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $150.78 | $16.25 |
| 52-week low | $1.92 | $1.00 |
| Distance from 52-week high | -96.70% | -93.05% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +1403.54% |
| Average volume | 94.85K | 85.87K |
| Shares outstanding | — | 14.59M |
| Employees | 12 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RADX has outperformed PBM by 11.7 percentage points over the past year.
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
PBM vs RADX FAQ
Which stock has performed better over the past year, PBM or RADX?
RADX returned -84.83% over the past 12 months, compared with -96.56% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Psyence Biomedical and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.